Harvard Bioscience (NASDAQ:HBIO) received an upgrade to a “buy” rating from Wall Street Zen in a research report released on Saturday. This follows a series of mixed evaluations from various analysts regarding the company”s stock.
In a report issued on September 10, Benchmark downgraded its price target for Harvard Bioscience from $3.00 to $2.00, while assigning a “speculative buy” rating. Conversely, Weiss Ratings reaffirmed a “sell (e+)” rating on October 8, indicating a more cautious outlook on the stock.
Currently, one analyst rates the stock as a buy, another suggests holding, and a third recommends selling. According to data from MarketBeat.com, the average rating for the stock is “hold,” with an average price target of $2.00.
In recent trading activities, several hedge funds have altered their holdings in Harvard Bioscience. AMH Equity Ltd increased its position by 15.4% during the third quarter, now owning over 4 million shares valued at approximately $1.775 million after acquiring additional shares. Acadian Asset Management LLC raised its stake by 7.8% in the first quarter, owning over 1 million shares worth around $606,000 after making further purchases.
Additionally, Williams & Novak LLC expanded its holdings by 158.5% in the third quarter, acquiring nearly 276,000 shares valued at approximately $121,000. Pasadena Private Wealth LLC also increased its stake by 23.2% in the second quarter, now holding around 244,000 shares worth approximately $108,000.
Institutional investors collectively own 80.87% of Harvard Bioscience”s stock, highlighting significant institutional interest in the company.
Harvard Bioscience develops and manufactures technologies, products, and services for life science applications both domestically and internationally. The company offers a variety of cellular and molecular technology products, including infusion pumps, electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and precision scientific measuring equipment.
For those interested in staying updated on Harvard Bioscience and related companies, MarketBeat.com offers a free daily email newsletter summarizing the latest news and analyst ratings.
